Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine
08/2015
Journal Article
Authors:
Winokur, P.L.;
Patel, S.M.;
Brady, R.;
Chen, W.H.;
El-Kamary, S.S.;
Edwards, K.;
Creech, C.B.;
Frey, S.;
Keitel, W.A.;
Belshe, R.;
Walter, E.;
Bellamy, A.;
Hill, H.;
Group, T.V.T.E.U.H.3Nv
Secondary:
J Infect Dis
Volume:
212
Pagination:
525-530
URL:
http://www.ncbi.nlm.nih.gov/pubmed/25712967
Keywords:
H5n1; influenza; prime-boost; vaccine
Abstract:
Influenza A(H5N1) vaccination strategies that improve the speed of the immunological response and cross-clade protection are desired. We compared the immunogenicity of a single 15-mug or 90-mug dose of A/H5N1/Indonesia/05/05 (clade 2) vaccine in adults who were previously primed with A/H5N1/Vietnam/1203/2004 (clade 1) vaccine. High-dose vaccine resulted in significantly higher titers to both clade 1 and 2 antigens. Clade 2 titers were unaffected by the previous dose of clade 1 vaccine. Low-dose priming with a mismatched pandemic influenza A(H5N1) vaccine would improve the rapidity, magnitude, and cross-reactivity of the immunological response following a single high-dose, unadjuvanted, pandemic vaccine.
